Bausch + Lomb Corp
🇺🇸XNYS.BLCOUnited StatesHealthcare
Price$16.86+0.04 (+0.24%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 0
- Medium: 1
- Low: 0
Gross profit margin: a sudden drop below its trailing quarter average
Free with a Finzer account.
Profile
- Healthcare
- Medical Instruments & Supplies
- United States
Identity
- Exchange
- New York Stock Exchange . XNYS
- Type
- Stock
- ISIN
- CA0717051076
- CUSIP
- Not reported
Company
- Employees
- 13,500
- Headquarters
- Vaughan, United States
- Website
- https://www.bausch.com
Market
- Shares outstanding
- 357.2M
- Market cap
- $5.99B
Key dates
- Next earnings
- Nov 4, 2026
Highlights
- Market cap
- $6.05B
- EPS LTM
- -$0.77
- P/E LTM
- -27.04
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- $4.89B+8.81%up year on year
- Net income
- -$273M+40.13%up year on year
- Gross margin
- 59.68%-1.91%down year on year
- Free cash flow
- -$165M-23.13%down year on year
Latest news
Business summary
Bausch + Lomb Corp is a company in the healthcare sector, listed on New York Stock Exchange (United States) under the ticker BLCO. Its market capitalisation is $5.99B, from 357.2M shares outstanding, as of . Across the 250 trading sessions to the shares traded between $13.77 and $18.87, and the last close of $16.86 sits 61% of the way up that range. The company is headquartered in Vaughan, United States, and employs about 13,500 people. This is the New York Stock Exchange listing of Bausch + Lomb Corp; its primary listing is BLCO on Toronto Stock Exchange.
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.